(Bloomberg) -- Moderna (NASDAQ:MRNA) Inc.’s shares have dropped 50% this year as investors pulled back from Covid-19 healthcare stocks and staged a broader rotation out of growth names.
The biotech firm fell as much as 7.3% on Monday amid a broader market selloff and has erased more than $50 billion in value this year. Investors were concerned over the future revenue of Covid-19 vaccines and increasing competition in the space. The stock has lost more than 70% from its record closing high of $484.47 set in August 2021.
“Increasing competition and lack of visibility” about future sales has led to a loss of investor interest across the Covid-19 complex, Oppenheimer analyst Hartaj Singh, who has a market perform rating on Moderna, said in an interview.
Moderna soared during the pandemic as it raced to develop a Covid-19 vaccine. Its 143% gain last year made it the third-best stock in the S&P 500. It’s been on a breakneck ascent upward since debuting in 2018, skyrocketing by 434% in 2020.
By 2022, investors were looking ahead to future Covid-19 vaccine demand amid growing debate about the timing and need for boosters, as interest in pandemic-focused healthcare names waned. Impending Federal Reserve interest-rate hikes and the ongoing Russia-Ukraine war have also hurt sentiment across global stock markets. The S&P 500 Index has dropped 11% this year, while the Nasdaq 100 Index is down 17%.
Among other vaccine makers, BioNTech SE (NASDAQ:BNTX) and Novavax (NASDAQ:NVAX) Inc. have each fallen by at least 50% this year, while the S&P 500 Health Care Index has declined 7.9%.
“I think there’s a Covid loss of interest,” SVB Leerink analyst Daina Graybosch, who has a market perform rating on BioNTech and does not cover Moderna, said in an interview. “I see it across the board.”
©2022 Bloomberg L.P.